mTOR-understanding the clinical effects.

Détails

ID Serval
serval:BIB_26D046EC5F82
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
mTOR-understanding the clinical effects.
Périodique
Transplantation Proceedings
Auteur⸱e⸱s
Contreras A.G., Dormond O., Edelbauer M., Calzadilla K., Hoerning A., Pal S., Briscoe D.M.
ISSN
0041-1345, 0041-1345[linking]
Statut éditorial
Publié
Date de publication
2008
Volume
40
Numéro
10 Suppl.
Pages
S9-S12
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
The target of rapamycin (TOR) is a highly conserved serine/threonine kinase that controls cell growth and metabolism in response to nutrients, growth factors, cellular energy, and stress. The TOR kinase, which was originally discovered in yeast, is also expressed in human cells as mammalian TOR (mTOR). In this review, we focus on how mTOR-inducible signals function in cell protection and cell survival of effector and regulatory T cells as well as its role in endothelial cell biology. We evaluate how signaling is important for vascular endothelial cell growth, survival, and proliferation; and we consider how the function of mTOR in endothelial cells may be clinically important in the rejection process. Understanding the biology of mTOR allows clinicians to use mTOR inhibitors optimally as therapeutics following solid organ transplantation.
Mots-clé
1-Phosphatidylinositol 3-Kinase/physiology, Animals, Graft Rejection/pathology, Graft Rejection/physiopathology, Humans, Inflammation/physiopathology, Mammals, Neovascularization, Pathologic/physiopathology, Protein Kinases/physiology, Signal Transduction, Transplantation, Homologous/pathology, Vascular Endothelial Growth Factor A/physiology
Pubmed
Création de la notice
17/02/2010 11:16
Dernière modification de la notice
20/08/2019 14:05
Données d'usage